BLCO: Nilai perusahaan marang bathi resik Bausch & Lomb

Lambang korporat lan logo Bausch + Lomb Corp (BLCO)

Bausch + Lomb Corporation (BLCO) generates stable income based on regular sales of ophthalmological consumables, which create a steady cash flow. The P/E ratio based on net income visualizes this trend, where the -65.80 indicator determines the magnitude of the metric. Growth prospects are tied to the promotion of the drug Miebo and premium lenses, while Brent Saunders' asset optimization strategy sustains investor confidence.

BLCO Bausch + Lomb Corp: Koefisien rega marang bathi ing interval 28.04.2023 - 17.11.2026

Rincian analitis perusahaan Bausch + Lomb Corporation

- rega lan prakiraan konsensus rega:
Ringkesan analisis perusahaan:Bausch + Lomb
Produk asli Bausch + Lomb Corporation

Bausch + Lomb Corporation (BLCO) maintains its status as the gold standard in ophthalmology, leveraging the unrivaled trust of the global medical community in its products. This price-to-earnings ratio reflects the market consensus regarding the cost per unit of profit, allowing for an assessment of the asset's overbought condition and its sensitivity to interest rates through the multiple compression trend on the chart.